1. The role of endoscopy in inflammatory bowel disease
Amandeep K. Shergill, MD, Jenifer R. Lightdale, MD, MPH, David H. Bruining, MD, Ruben D. Acosta, MD, Vinay Chandrasekhara, MD, Krishnavel V. Chathadi, MD, G. Anton Decker, MBBCh, MRCP, MHA, Dayna S. Early, MD, John A. Evans, MD, Robert D. Fanelli, MD, Deborah A. Fisher, MD, MHS, Lisa Fonkalsrud, BSN, RN, Kimberly Foley, RN, BSN, CGRN, Joo Ha Hwang, MD, PhD, Terry L. Jue, MD, Mouen A. Khashab, MD, V. Raman Muthusamy, MD, Shabana F. Pasha, MD, John R. Saltzman, MD, Ravi Sharaf, MD, Brooks D. Cash, MD, John M. DeWitt, MD 
Gastrointestinal Endoscopy 
Volume 81, Issue 5, Pages e13 (May 2015)
DOI: /j.gie
Copyright © 2015 American Society for Gastrointestinal Endoscopy Terms and Conditions

2. Figure 1
Description of endoscopically visible lesions (Paris Classification)219,222
*2.5 mm = size of closed cup of biopsy forceps.
**Also include location (within or outside an area of known colitis), borders (distinct or indistinct), and presence of ulceration and/or other features of submucosal invasion.
***Morphological combinations of lesions can occur.
Gastrointestinal Endoscopy  , e13DOI: ( /j.gie )
Copyright © 2015 American Society for Gastrointestinal Endoscopy Terms and Conditions

3. Figure 2
Recommended management of lesion detected during endoscopic surveillance. EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection.
*Features of submucosal invasion include: depressions, failure to lift with attempted submucosal injection, or presence of overlying ulceration.
Gastrointestinal Endoscopy  , e13DOI: ( /j.gie )
Copyright © 2015 American Society for Gastrointestinal Endoscopy Terms and Conditions